ARTICLE | Company News
Audentes Therapeutics, ReGenX deal
August 5, 2013 7:00 AM UTC
ReGenX granted Audentes exclusive, worldwide rights to use NAV rAAV8 and rAAV9 vectors to develop and commercialize products to treat X-linked myotubular myopathy and Pompe's disease. ReGenX will rece...